DUBLIN and HOUSTON, Aug. 6, 2018 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes. The joint effort brings …
Tag Archives: Jazz Pharmaceuticals
August, 2018
July, 2018
-
20 July
Positive Phase 3 Data of Jazz’s Vyxeos in Patients with Acute Myeloid Leukemia Published in Journal of Clinical Oncology
DUBLIN, July 19, 2018 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that data from the pivotal Phase 3 study of Vyxeos® (daunorubicin and cytarabine) liposome for injection compared to standard of care cytarabine and daunorubicin (7+3) were published online in the Journal of Clinical Oncology. The study evaluated the efficacy and safety …
August, 2017
-
3 August
Jazz’s Vyxeos Receives FDA Approval for Treatment of Certain Poor Prognosis Acute Myeloid Leukemia
DUBLIN, Aug. 3, 2017 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has approved Vyxeos™ (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of Acute Myeloid Leukemia (AML), a rapidly progressing and life-threatening blood cancer. …
July, 2017
-
27 July
Jazz Pharmaceuticals to Use XL-Protein’s Technology Platform to Develop Long-Acting Asparaginase Product Candidates
DUBLIN, July 26, 2017 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a license agreement with XL-protein GmbH (“XLp”) for the rights to develop, manufacture and commercialize products using XLp’s PASylation® Technology to extend the plasma half-life of selected asparaginase product candidates. Under the …
June, 2017
-
1 June
FDA Grants Priority Review to Jazz Pharmaceuticals’ NDA for Vyxeos in Acute Myeloid Leukemia
DUBLIN, May 31, 2017 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ)today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for VYXEOS™ (cytarabine and daunorubicin) liposome injection, an investigational treatment for acute myeloid leukemia (AML), a …
August, 2016
-
1 August
Jazz Enters Hematological Malignancies Licensing Deal with Pfenex
DUBLIN and SAN DIEGO, July 28, 2016 /PRNewswire/ — Jazz Pharmaceuticals plc(Nasdaq: JAZZ) and Pfenex Inc. (NYSE MKT: PFNX) today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals …
May, 2016
-
12 May
Jazz Pharmaceuticals Purchases Alize Pharma
Alizé Pharma II announces today that a subsidiary of Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has acquired 100% of its shares. This all-cash transaction closed in March 2016. The deal is valued at up to €18 million, including an upfront payment of €8 million and potential payments of up to €10 …
March, 2016
-
31 March
FDA Approves Jazz Pharmaceuticals’ Rare Liver Disease Drug
DUBLIN, March 30, 2016 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States (U.S.) Food and Drug Administration (FDA) granted marketing approval for Defitelio® (defibrotide sodium) for the treatment of adult and pediatric patients with hepatic VOD, also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary …